SCHEMBL442239

SCHEMBL442239

NC(=O)Oc1cc(F)cc(F)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
CES2 O00748 3/20 0.42
CES1 P23141 3/20 0.42
KIF11 P52732 1/20 0.41
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA9 Q16790 1/20 0.36
PARP1 P09874 2/20 0.34
IDO1 P14902 2/20 0.33
FAAH O00519 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
SOD1 P00441 1/20 0.32
SLC9A1 P19634 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27560290 0.86 MEN1 (0.44) MEN1KMT2ACYP4F2CYP4A11KIF11
SCHEMBL29177324 0.86 MEN1 (0.44) MEN1KMT2ACYP4F2CYP4A11KIF11
SCHEMBL27574759 0.86 MEN1 (0.44) MEN1KMT2ACYP4F2CYP4A11CES2
SCHEMBL27091828 0.82 KMT2A (0.46) MEN1KMT2ACYP4F2CYP4A11CES2
SCHEMBL5245392 0.82 KIF11 (0.53) MEN1KMT2ACYP4F2CYP4A11CES2
SCHEMBL28292318 0.82 MEN1 (0.41) MEN1KMT2ACYP4F2CYP4A11KIF11
SCHEMBL27944749 0.81 MEN1 (0.40) MEN1KMT2ACYP4F2CYP4A11KIF11
SCHEMBL28284733 0.81 MGLL (0.45) MEN1KMT2A
SCHEMBL21810570 0.80 CYP4F2 (0.47) MEN1KMT2ACYP4F2CYP4A11CES2
SCHEMBL28181342 0.79 MEN1 (0.50) MEN1KMT2ACYP4F2CYP4A11CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033952-A1 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS MICURX PHARMACEUTICALS, INC. (KY) 2012-03-15 WO disclosed
US-20120065170-A1 Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections MICURX PHARMACEUTICALS, INC. (KY) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065170-A1 Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections NISCH, SI, VIP MEN1 2653/4885KMT2A 4753/4885CYP4F2 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.